γδTCR CDR3 Chain Identification for Anti-Tumour Response

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing technologies have limitations in addressing the need for improved γδT-cell receptor chains for immunotherapeutic applications in addressing the need for identifying new γδTCRs that will mediate an anti-tumour response.

Innovation Solution

The γδTCR chains or parts thereof are engineered to mediate an anti-infective response by providing a method for identifying the γδTCR or parts thereof comprising a CDR3 region.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If new γδTCR chains are identified and engineered for anti-tumour response, then the anti-tumour efficacy is improved, but the complexity of identification and characterization increases

Engineering Contradiction:

Improveanti-tumour efficacyVSAvoidcomplexity of identification and characterization

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent segments the γδTCR identification process into distinct components: isolating TCR chains from γδTCRs, characterizing their CDR3 regions, and testing their anti-tumour activity. This segmentation allows systematic identification and characterization of multiple TCR chains with different specificities, improving anti-tumour efficacy while managing complexity through structured approaches.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent utilizes parameter changes in the CDR3 region sequences of γδTCR chains to generate diversity in antigen recognition. By identifying and engineering variations in the CDR3 loops (particularly in γ and δ chains), the patent creates TCR chains with enhanced or altered anti-tumour specificities, directly improving therapeutic efficacy through sequence optimization.

Inventive Principle:

Principle #35Parameter changes

2Adaptability or versatility

If γδTCR chains with high diversity in CDR3 loop are utilized, then the potential to recognize various tumour antigens is improved, but the difficulty of identifying functional chains increases

Engineering Contradiction:

Improvepotential to recognize various tumour antigensVSAvoiddifficulty of identifying functional chains

Core Design Contradiction:

Adaptability or versatilityVSDifficulty of detecting and measuring

Solution Approach 1:

The patent performs preliminary characterization of γδTCR chains by isolating and sequencing their CDR3 regions before functional testing. This preliminary action involves cataloging the diversity of CDR3 sequences, predicting their antigen-binding potential, and prioritizing candidates for subsequent anti-tumour activity assays, thereby systematically managing the identification process despite high sequence diversity.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent employs feedback mechanisms by testing the anti-tumour activity of engineered γδTCR chains and using the results to guide further identification and engineering efforts. Successful chains with demonstrated anti-tumour activity provide feedback on which CDR3 region characteristics are functionally important, refining the identification criteria for subsequent candidates.

Inventive Principle:

Principle #23Feedback

Data Source

PatentUS20250368716A1Delta t-cell or gamma t-cell receptor chains or parts thereof that mediate an Anti-tumour or Anti-infective response

Publication Date: 2025.12.04 GADETA BV

AI summary

We identified several novel δT-cell and γT-cell receptor chains mediating anti-tumour or anti-infective responses as well as methods for identifying same.